Datametrex AI (TSXV: DM) is taking the next step with its telehealth app. The firm this morning announced that is has officially launched the beta version of the Medi-Call app as it enters the next phase of development.
The app is opening to beta testers in Ontario and Quebec as of this morning, with a “focused group” of both physicians and end users being selected for the initial launch of the program. Testing will initially focus on the user experience for both clients and physicians, to enable the firm to make any necessary changes before the program goes live for a broader audience.
Medi-Call is effectively looking to provide faster care and treatment for its patients, while also enabling physicians to better manage their appointments. The app aims to solve accessibility issues for rural or isolated communities, while improving coordination for healthcare team members. The telehealth market as a whole is estimated to hit $830 billion globally by 2027.
“To get the app ready for beta testing in this short period is a milestone for the Company and shows our commitment and belief in the potential of the sector. With this new application, we are looking forward to meeting the growing demand from physicians and potential patients by taking the next step to capture the full potential of Medi-Call’s services,” commented CEO Marshall Gunter.
Datametrex AI last traded at $0.17 on the TSX Venture.
FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.